An open-label, randomized, single center prospective study to evaluate the efficacy & safety of a polyherbal NEERIÂ® Tablet and Syrup in patients with renal calculi disease - NI

Aimil Pharmaceuticals (India) Ltd.0 个研究点目标入组 0 人开始时间: 待定最近更新: 2023年7月25日

试验速览

暂无简介。

•1.Participants of either sex aged 18 to 65 years
•2.Willing to sign informed consent and comply with the requirements of the study protocol
•3.Participants with diagnostic reports (plain X-ray, ultrasound sonography, or CT scan) for renal calculi.
•4.Participants with the calculi size ranging from 4 mm to less than 10 mm.

•1.Pregnant and lactating women
•2.Known allergies to any component of the study intervention.
•3.Patients with acute or complicated conditions of kidney stones.
•4.Subjects who have taken other drugs or herbal supplements for stone disease in the previous 3 months.
•5.Participants with chronic or active disease, such as kidney failure, liver disorder, cancer, myocardial infarction, uncontrolled diabetes, uncontrolled hypertension, symptomatic congestive heart failure, and chronic kidney infection.
•6.Evidence of significant concomitant disease that, in the view of the principal investigator, that would prevent patient participation
•7.Participants suffering from a mental illness or other condition that would make it difficult to meet the study requirements.

发起方

Aimil Pharmaceuticals (India) Ltd.